Unigene Initiates Oral Calcitonin Clinical Study in Humans

Unigene Laboratories announced that it has initiated a clinical study in the U.S. with its proprietary formulation of oral calcitonin for the treatment of osteoporosis.

The tablets used in the study will utilize an improved solid dosage form of the company’s Enteripep oral delivery technology, Unigene said.

The novel dosage form is the subject of a recently filed patent application and has already been shown in animal studies to deliver a more consistent dose of calcitonin while maintaining therapeutic blood levels of this peptide, the company added.